Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetic Retinopathy | 123 | 2024 | 1210 | 20.610 |
Why?
|
Macular Edema | 53 | 2023 | 359 | 11.500 |
Why?
|
Visual Acuity | 48 | 2023 | 2530 | 4.840 |
Why?
|
Angiogenesis Inhibitors | 44 | 2023 | 2038 | 4.830 |
Why?
|
Retina | 38 | 2023 | 2616 | 3.850 |
Why?
|
Diabetes Mellitus | 38 | 2024 | 5751 | 3.630 |
Why?
|
Retinal Vessels | 18 | 2023 | 772 | 3.410 |
Why?
|
Fluorescein Angiography | 16 | 2022 | 940 | 2.660 |
Why?
|
Intravitreal Injections | 34 | 2023 | 344 | 2.410 |
Why?
|
Tomography, Optical Coherence | 39 | 2023 | 2657 | 2.370 |
Why?
|
Laser Coagulation | 15 | 2020 | 326 | 2.160 |
Why?
|
Photography | 16 | 2022 | 520 | 2.100 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 17 | 2023 | 664 | 1.750 |
Why?
|
Ophthalmoscopy | 7 | 2022 | 176 | 1.730 |
Why?
|
Vascular Endothelial Growth Factor A | 33 | 2023 | 3508 | 1.680 |
Why?
|
Diabetes Mellitus, Type 1 | 25 | 2023 | 3336 | 1.580 |
Why?
|
Optics and Photonics | 4 | 2022 | 321 | 1.290 |
Why?
|
Recombinant Fusion Proteins | 16 | 2023 | 3772 | 1.110 |
Why?
|
Vitrectomy | 10 | 2021 | 365 | 1.060 |
Why?
|
Diagnostic Techniques, Ophthalmological | 7 | 2022 | 245 | 0.880 |
Why?
|
Retinal Neovascularization | 6 | 2019 | 244 | 0.850 |
Why?
|
Glucocorticoids | 6 | 2021 | 2107 | 0.800 |
Why?
|
Fundus Oculi | 8 | 2021 | 473 | 0.800 |
Why?
|
Telepathology | 3 | 2016 | 76 | 0.790 |
Why?
|
Self Concept | 2 | 2017 | 1025 | 0.770 |
Why?
|
Macula Lutea | 4 | 2022 | 151 | 0.760 |
Why?
|
Central Serous Chorioretinopathy | 1 | 2021 | 27 | 0.750 |
Why?
|
Endothelial Growth Factors | 1 | 2023 | 694 | 0.740 |
Why?
|
Enema | 1 | 2021 | 141 | 0.740 |
Why?
|
Vitreous Body | 5 | 2022 | 389 | 0.730 |
Why?
|
Refraction, Ocular | 2 | 2011 | 182 | 0.720 |
Why?
|
Vascular Endothelial Growth Factors | 2 | 2022 | 772 | 0.690 |
Why?
|
Blindness | 1 | 2023 | 617 | 0.660 |
Why?
|
Choroid | 1 | 2020 | 322 | 0.660 |
Why?
|
Social Sciences | 1 | 2018 | 45 | 0.620 |
Why?
|
Cataract | 4 | 2017 | 834 | 0.620 |
Why?
|
Endocrinology | 5 | 2023 | 443 | 0.600 |
Why?
|
Clinical Protocols | 3 | 2020 | 1462 | 0.590 |
Why?
|
Cataract Extraction | 3 | 2020 | 481 | 0.570 |
Why?
|
Humans | 166 | 2024 | 744343 | 0.570 |
Why?
|
Reminder Systems | 1 | 2020 | 371 | 0.570 |
Why?
|
Retinal Vein Occlusion | 2 | 2017 | 137 | 0.570 |
Why?
|
Telephone | 1 | 2020 | 617 | 0.560 |
Why?
|
Vision Disorders | 6 | 2023 | 1058 | 0.540 |
Why?
|
Vision Tests | 3 | 2011 | 167 | 0.530 |
Why?
|
Vision, Low | 1 | 2017 | 168 | 0.530 |
Why?
|
Eye Proteins | 3 | 2022 | 646 | 0.520 |
Why?
|
Retinal Cone Photoreceptor Cells | 1 | 2016 | 177 | 0.520 |
Why?
|
Multiple Myeloma | 6 | 2022 | 5181 | 0.510 |
Why?
|
Telemedicine | 7 | 2023 | 2872 | 0.470 |
Why?
|
Pupil | 4 | 2016 | 149 | 0.470 |
Why?
|
Triamcinolone Acetonide | 3 | 2011 | 101 | 0.460 |
Why?
|
Middle Aged | 80 | 2023 | 213383 | 0.440 |
Why?
|
Diagnosis, Computer-Assisted | 2 | 2016 | 719 | 0.430 |
Why?
|
Mass Screening | 2 | 2020 | 5255 | 0.430 |
Why?
|
Diabetes Mellitus, Type 2 | 16 | 2023 | 11725 | 0.420 |
Why?
|
Mydriatics | 5 | 2022 | 68 | 0.410 |
Why?
|
Ophthalmology | 4 | 2023 | 508 | 0.400 |
Why?
|
Retinal Diseases | 4 | 2023 | 683 | 0.390 |
Why?
|
Macular Degeneration | 4 | 2023 | 980 | 0.390 |
Why?
|
Follow-Up Studies | 21 | 2023 | 39050 | 0.380 |
Why?
|
Diabetes Complications | 3 | 2014 | 1359 | 0.380 |
Why?
|
Diabetic Nephropathies | 6 | 2019 | 984 | 0.370 |
Why?
|
Light Coagulation | 3 | 2020 | 72 | 0.370 |
Why?
|
Male | 86 | 2023 | 350118 | 0.370 |
Why?
|
Patient Participation | 1 | 2020 | 1457 | 0.370 |
Why?
|
Disease Management | 2 | 2018 | 2459 | 0.360 |
Why?
|
Algorithms | 3 | 2020 | 13881 | 0.360 |
Why?
|
Female | 88 | 2023 | 380194 | 0.350 |
Why?
|
Attitude to Health | 2 | 2017 | 2052 | 0.330 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2021 | 9959 | 0.320 |
Why?
|
Artificial Intelligence | 2 | 2023 | 2214 | 0.320 |
Why?
|
Aging | 2 | 2017 | 8664 | 0.310 |
Why?
|
Diagnostic Imaging | 5 | 2016 | 3507 | 0.300 |
Why?
|
Disease Progression | 16 | 2024 | 13284 | 0.300 |
Why?
|
Aged | 54 | 2023 | 163280 | 0.300 |
Why?
|
Cross-Sectional Studies | 14 | 2021 | 25043 | 0.280 |
Why?
|
Choroidal Neovascularization | 2 | 2012 | 343 | 0.280 |
Why?
|
Vitreous Hemorrhage | 3 | 2021 | 48 | 0.270 |
Why?
|
Diabetic Angiopathies | 3 | 2018 | 818 | 0.260 |
Why?
|
Kallikrein-Kinin System | 2 | 2016 | 9 | 0.260 |
Why?
|
Vitreoretinopathy, Proliferative | 2 | 2004 | 68 | 0.260 |
Why?
|
Severity of Illness Index | 13 | 2021 | 15540 | 0.250 |
Why?
|
Nanoparticles | 3 | 2021 | 1905 | 0.240 |
Why?
|
Aptamers, Nucleotide | 2 | 2016 | 166 | 0.230 |
Why?
|
Eye | 3 | 2024 | 729 | 0.230 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 7279 | 0.230 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 3022 | 0.230 |
Why?
|
Retinol-Binding Proteins | 2 | 2022 | 65 | 0.230 |
Why?
|
Proteome | 1 | 2013 | 1799 | 0.230 |
Why?
|
Retrospective Studies | 22 | 2023 | 77449 | 0.220 |
Why?
|
Treatment Outcome | 18 | 2023 | 63114 | 0.220 |
Why?
|
Adult | 39 | 2022 | 214055 | 0.220 |
Why?
|
Mydriasis | 1 | 2022 | 15 | 0.210 |
Why?
|
Plasma Kallikrein | 2 | 2019 | 20 | 0.210 |
Why?
|
Antibodies, Monoclonal | 3 | 2021 | 9274 | 0.200 |
Why?
|
Vitreous Detachment | 1 | 2021 | 22 | 0.200 |
Why?
|
Retinal Neurons | 1 | 2021 | 66 | 0.190 |
Why?
|
Tumor Microenvironment | 3 | 2022 | 3586 | 0.190 |
Why?
|
Tissue Culture Techniques | 1 | 2021 | 290 | 0.180 |
Why?
|
Retinal Detachment | 3 | 2020 | 411 | 0.180 |
Why?
|
Health Services Accessibility | 1 | 2017 | 5137 | 0.180 |
Why?
|
Injections, Intralesional | 1 | 2020 | 276 | 0.180 |
Why?
|
Biology | 1 | 2022 | 294 | 0.180 |
Why?
|
Antibodies, Bispecific | 1 | 2022 | 164 | 0.180 |
Why?
|
Boron Neutron Capture Therapy | 1 | 2019 | 51 | 0.170 |
Why?
|
Lost to Follow-Up | 1 | 2020 | 105 | 0.170 |
Why?
|
Retinal Hemorrhage | 2 | 2017 | 96 | 0.170 |
Why?
|
Liposomes | 2 | 2020 | 759 | 0.170 |
Why?
|
Copper Radioisotopes | 1 | 2019 | 86 | 0.170 |
Why?
|
rho-Associated Kinases | 1 | 2020 | 279 | 0.170 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2013 | 15519 | 0.170 |
Why?
|
Antineoplastic Agents | 5 | 2022 | 13695 | 0.160 |
Why?
|
Reproducibility of Results | 7 | 2020 | 19905 | 0.160 |
Why?
|
Benzylamines | 1 | 2019 | 223 | 0.160 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2020 | 358 | 0.160 |
Why?
|
Cohort Studies | 12 | 2023 | 40561 | 0.160 |
Why?
|
Fluorocarbons | 2 | 2021 | 452 | 0.160 |
Why?
|
Boron Compounds | 1 | 2019 | 178 | 0.160 |
Why?
|
Edema | 1 | 2022 | 789 | 0.150 |
Why?
|
Immunotherapy | 3 | 2022 | 4445 | 0.150 |
Why?
|
Vision Screening | 1 | 2018 | 66 | 0.150 |
Why?
|
Humanities | 1 | 2018 | 53 | 0.150 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2023 | 685 | 0.150 |
Why?
|
Angiography | 2 | 2021 | 1639 | 0.150 |
Why?
|
Hospitalization | 1 | 2017 | 10262 | 0.150 |
Why?
|
Whipple Disease | 1 | 2016 | 19 | 0.140 |
Why?
|
Allied Health Occupations | 1 | 2016 | 4 | 0.140 |
Why?
|
Postoperative Complications | 3 | 2020 | 15295 | 0.140 |
Why?
|
Societies, Medical | 4 | 2023 | 3743 | 0.140 |
Why?
|
Double-Blind Method | 5 | 2022 | 12026 | 0.140 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2021 | 689 | 0.140 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2022 | 3523 | 0.140 |
Why?
|
Calmodulin | 1 | 2016 | 209 | 0.130 |
Why?
|
Cross-Over Studies | 2 | 2018 | 2029 | 0.130 |
Why?
|
Sigmodontinae | 1 | 2015 | 7 | 0.130 |
Why?
|
Crystallins | 3 | 2000 | 75 | 0.130 |
Why?
|
Albumins | 1 | 2018 | 569 | 0.130 |
Why?
|
Electroretinography | 1 | 2017 | 509 | 0.130 |
Why?
|
Fovea Centralis | 1 | 2015 | 119 | 0.130 |
Why?
|
Prospective Studies | 16 | 2023 | 53288 | 0.130 |
Why?
|
Reference Standards | 3 | 2023 | 1025 | 0.130 |
Why?
|
Watchful Waiting | 1 | 2019 | 492 | 0.130 |
Why?
|
Respiratory Syncytial Virus Vaccines | 1 | 2015 | 32 | 0.120 |
Why?
|
Standard of Care | 3 | 2023 | 564 | 0.120 |
Why?
|
Emulsions | 1 | 2015 | 156 | 0.120 |
Why?
|
Receptors, CXCR4 | 1 | 2019 | 726 | 0.120 |
Why?
|
Health Occupations | 1 | 2016 | 224 | 0.120 |
Why?
|
Cisplatin | 1 | 2020 | 1662 | 0.120 |
Why?
|
Hydrodynamics | 1 | 2015 | 158 | 0.120 |
Why?
|
Vaccines, Inactivated | 1 | 2015 | 184 | 0.120 |
Why?
|
Carbonic Anhydrase I | 1 | 2013 | 4 | 0.120 |
Why?
|
Aldehyde Reductase | 1 | 2013 | 65 | 0.120 |
Why?
|
Endophthalmitis | 1 | 2016 | 262 | 0.120 |
Why?
|
T-Lymphocytes | 2 | 2022 | 10180 | 0.120 |
Why?
|
Tropicamide | 2 | 2013 | 23 | 0.110 |
Why?
|
Wet Macular Degeneration | 1 | 2015 | 145 | 0.110 |
Why?
|
Ophthalmic Solutions | 1 | 2014 | 317 | 0.110 |
Why?
|
Aged, 80 and over | 16 | 2021 | 57776 | 0.110 |
Why?
|
Visual Fields | 1 | 2020 | 1047 | 0.110 |
Why?
|
Ophthalmoscopes | 1 | 2012 | 23 | 0.110 |
Why?
|
Lasers | 3 | 2022 | 952 | 0.110 |
Why?
|
Cost-Benefit Analysis | 3 | 2023 | 5391 | 0.110 |
Why?
|
Drug Substitution | 1 | 2015 | 281 | 0.110 |
Why?
|
Antigens, Neoplasm | 1 | 2021 | 1988 | 0.110 |
Why?
|
Phacoemulsification | 1 | 2014 | 149 | 0.110 |
Why?
|
Lens Implantation, Intraocular | 1 | 2014 | 192 | 0.110 |
Why?
|
Creatinine | 1 | 2018 | 1919 | 0.110 |
Why?
|
Phenylephrine | 2 | 2013 | 301 | 0.100 |
Why?
|
Endocarditis | 1 | 2016 | 350 | 0.100 |
Why?
|
Transforming Growth Factor beta | 1 | 2000 | 2007 | 0.100 |
Why?
|
Cardiovascular Diseases | 6 | 2018 | 15165 | 0.100 |
Why?
|
Long QT Syndrome | 1 | 2016 | 453 | 0.100 |
Why?
|
Neovascularization, Pathologic | 1 | 2022 | 2635 | 0.100 |
Why?
|
Artifacts | 1 | 2020 | 1904 | 0.100 |
Why?
|
Time Factors | 9 | 2020 | 40075 | 0.100 |
Why?
|
Bone Marrow | 1 | 2021 | 2948 | 0.100 |
Why?
|
Peripheral Vascular Diseases | 1 | 2014 | 550 | 0.100 |
Why?
|
Dexamethasone | 1 | 2018 | 1951 | 0.090 |
Why?
|
Membrane Glycoproteins | 2 | 2020 | 3768 | 0.090 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2015 | 329 | 0.090 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2019 | 1052 | 0.090 |
Why?
|
Combined Modality Therapy | 5 | 2012 | 8642 | 0.090 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 1596 | 0.090 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2013 | 360 | 0.090 |
Why?
|
Interprofessional Relations | 1 | 2016 | 1011 | 0.090 |
Why?
|
Radiopharmaceuticals | 1 | 2019 | 2645 | 0.090 |
Why?
|
Office Visits | 1 | 2013 | 598 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10943 | 0.080 |
Why?
|
Personal Satisfaction | 1 | 2013 | 643 | 0.080 |
Why?
|
Cognition | 3 | 2021 | 6770 | 0.080 |
Why?
|
Hyperthermia, Induced | 2 | 2019 | 403 | 0.080 |
Why?
|
Pulsatile Flow | 1 | 2010 | 332 | 0.080 |
Why?
|
Culture | 1 | 2013 | 633 | 0.080 |
Why?
|
Colitis, Ulcerative | 1 | 2021 | 1912 | 0.080 |
Why?
|
Tumor Cells, Cultured | 3 | 2021 | 6314 | 0.080 |
Why?
|
Retreatment | 1 | 2010 | 610 | 0.080 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2020 | 2020 | 0.080 |
Why?
|
Young Adult | 10 | 2018 | 56430 | 0.080 |
Why?
|
Computer Simulation | 1 | 2022 | 6196 | 0.080 |
Why?
|
Polypharmacy | 1 | 2010 | 294 | 0.080 |
Why?
|
Tachycardia, Ventricular | 1 | 2016 | 1273 | 0.080 |
Why?
|
Drug Combinations | 2 | 2013 | 1959 | 0.080 |
Why?
|
Arginine | 1 | 2011 | 944 | 0.070 |
Why?
|
Receptors, Immunologic | 1 | 2013 | 1423 | 0.070 |
Why?
|
Injections | 1 | 2010 | 840 | 0.070 |
Why?
|
Vitreoretinal Surgery | 2 | 2017 | 27 | 0.070 |
Why?
|
Lens, Crystalline | 2 | 1999 | 388 | 0.070 |
Why?
|
Canada | 2 | 2022 | 2065 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2019 | 2538 | 0.070 |
Why?
|
Lysine | 1 | 2011 | 1007 | 0.070 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 7913 | 0.070 |
Why?
|
United States | 9 | 2023 | 69872 | 0.070 |
Why?
|
Tissue Distribution | 2 | 2020 | 2327 | 0.070 |
Why?
|
Awards and Prizes | 1 | 2010 | 375 | 0.070 |
Why?
|
Adolescent | 8 | 2022 | 85781 | 0.070 |
Why?
|
Logistic Models | 2 | 2018 | 13408 | 0.070 |
Why?
|
Insulin | 2 | 2010 | 6580 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2018 | 3528 | 0.060 |
Why?
|
Blood Glucose | 2 | 2017 | 6256 | 0.060 |
Why?
|
Hemodynamics | 1 | 2015 | 4199 | 0.060 |
Why?
|
Antibodies, Neutralizing | 1 | 2015 | 1978 | 0.060 |
Why?
|
Tumor Burden | 2 | 2020 | 1915 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2020 | 5535 | 0.060 |
Why?
|
Education, Medical | 1 | 2016 | 1721 | 0.060 |
Why?
|
Mice, SCID | 2 | 2021 | 2716 | 0.060 |
Why?
|
Research Design | 1 | 2020 | 5987 | 0.060 |
Why?
|
Cognition Disorders | 1 | 2018 | 4043 | 0.060 |
Why?
|
Risk Factors | 9 | 2019 | 72290 | 0.060 |
Why?
|
Steroids | 1 | 2009 | 930 | 0.060 |
Why?
|
Erythropoietin | 1 | 2008 | 726 | 0.060 |
Why?
|
Antibodies, Viral | 1 | 2015 | 3176 | 0.060 |
Why?
|
Positron-Emission Tomography | 1 | 2019 | 6234 | 0.060 |
Why?
|
Mice, Nude | 2 | 2020 | 3689 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9239 | 0.060 |
Why?
|
Sensitivity and Specificity | 5 | 2019 | 14722 | 0.060 |
Why?
|
Cell Line, Tumor | 4 | 2020 | 16689 | 0.060 |
Why?
|
Motivation | 1 | 2013 | 1971 | 0.060 |
Why?
|
Insulin-Secreting Cells | 1 | 2010 | 891 | 0.050 |
Why?
|
Transcription Factors | 1 | 2022 | 12208 | 0.050 |
Why?
|
Phytohemagglutinins | 1 | 2022 | 170 | 0.050 |
Why?
|
Blood Pressure | 1 | 2018 | 8554 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2021 | 3557 | 0.050 |
Why?
|
Health Behavior | 1 | 2013 | 2636 | 0.050 |
Why?
|
Gene Expression | 3 | 2000 | 7799 | 0.050 |
Why?
|
Animals | 12 | 2021 | 168757 | 0.050 |
Why?
|
Case-Control Studies | 4 | 2022 | 21746 | 0.050 |
Why?
|
Blotting, Northern | 2 | 2000 | 1581 | 0.050 |
Why?
|
Quality of Life | 2 | 2013 | 12804 | 0.050 |
Why?
|
Angiopoietin-2 | 1 | 2022 | 173 | 0.050 |
Why?
|
Cell Proliferation | 3 | 2021 | 10481 | 0.050 |
Why?
|
Drug Therapy, Combination | 2 | 2018 | 6489 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11524 | 0.050 |
Why?
|
Inhibitory Concentration 50 | 1 | 2021 | 459 | 0.050 |
Why?
|
Evidence-Based Medicine | 3 | 2017 | 3610 | 0.050 |
Why?
|
Hematocrit | 1 | 2022 | 636 | 0.050 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 2020 | 182 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2023 | 5078 | 0.050 |
Why?
|
Drug Implants | 1 | 2020 | 244 | 0.040 |
Why?
|
3-O-Methylglucose | 1 | 2019 | 37 | 0.040 |
Why?
|
Eyelids | 1 | 2022 | 265 | 0.040 |
Why?
|
Retinal Perforations | 1 | 2021 | 131 | 0.040 |
Why?
|
Physicians | 1 | 2018 | 4567 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2022 | 13989 | 0.040 |
Why?
|
Pilot Projects | 2 | 2023 | 8324 | 0.040 |
Why?
|
Metallothionein | 1 | 1998 | 59 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 629 | 0.040 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2021 | 730 | 0.040 |
Why?
|
Acids | 1 | 2019 | 127 | 0.040 |
Why?
|
Nitroimidazoles | 1 | 2019 | 106 | 0.040 |
Why?
|
Deoxyglucose | 1 | 2019 | 337 | 0.040 |
Why?
|
Photochemotherapy | 1 | 2005 | 807 | 0.040 |
Why?
|
Observation | 1 | 2020 | 312 | 0.040 |
Why?
|
P-Selectin | 1 | 2020 | 600 | 0.040 |
Why?
|
Protective Agents | 1 | 2019 | 156 | 0.040 |
Why?
|
src-Family Kinases | 1 | 2020 | 551 | 0.040 |
Why?
|
Blood Flow Velocity | 1 | 2022 | 1423 | 0.040 |
Why?
|
Phenylalanine | 1 | 2019 | 365 | 0.040 |
Why?
|
Amides | 1 | 2020 | 459 | 0.040 |
Why?
|
Capillaries | 1 | 2021 | 773 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2000 | 4751 | 0.040 |
Why?
|
Cell Movement | 2 | 2020 | 5217 | 0.040 |
Why?
|
Photoreceptor Cells, Vertebrate | 1 | 2019 | 204 | 0.040 |
Why?
|
Radiotherapy | 1 | 2005 | 1533 | 0.040 |
Why?
|
Rats, Inbred Lew | 1 | 2019 | 1162 | 0.040 |
Why?
|
Enzymes | 1 | 1999 | 266 | 0.040 |
Why?
|
Cysteine Endopeptidases | 1 | 2000 | 563 | 0.040 |
Why?
|
Mice | 6 | 2021 | 81183 | 0.040 |
Why?
|
Coronary Disease | 1 | 2012 | 6077 | 0.040 |
Why?
|
Ryanodine | 1 | 2016 | 47 | 0.040 |
Why?
|
Phosphoprotein Phosphatases | 1 | 1998 | 337 | 0.040 |
Why?
|
Orchitis | 1 | 2016 | 35 | 0.040 |
Why?
|
Epididymitis | 1 | 2016 | 37 | 0.040 |
Why?
|
Finland | 1 | 2018 | 602 | 0.040 |
Why?
|
Chitosan | 1 | 2017 | 141 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2008 | 5867 | 0.040 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2019 | 595 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2019 | 546 | 0.040 |
Why?
|
Multienzyme Complexes | 1 | 2000 | 686 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2021 | 1878 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2021 | 1677 | 0.030 |
Why?
|
Ceftriaxone | 1 | 2016 | 168 | 0.030 |
Why?
|
Phospholipids | 1 | 2019 | 784 | 0.030 |
Why?
|
Hydrogen Peroxide | 1 | 1999 | 731 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2004 | 3479 | 0.030 |
Why?
|
RNA, Ribosomal, 16S | 1 | 1999 | 954 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2012 | 8949 | 0.030 |
Why?
|
Glycolysis | 1 | 2019 | 827 | 0.030 |
Why?
|
Cross Protection | 1 | 2015 | 24 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2022 | 3870 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2021 | 1681 | 0.030 |
Why?
|
Drug Resistance | 1 | 2021 | 1609 | 0.030 |
Why?
|
Particle Size | 1 | 2019 | 1642 | 0.030 |
Why?
|
Therapeutic Equivalency | 1 | 2015 | 141 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2971 | 0.030 |
Why?
|
Viral Fusion Proteins | 1 | 2015 | 95 | 0.030 |
Why?
|
Pseudophakia | 1 | 2014 | 62 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2015 | 426 | 0.030 |
Why?
|
Signal Processing, Computer-Assisted | 2 | 2012 | 1534 | 0.030 |
Why?
|
Apoptosis | 2 | 2021 | 9727 | 0.030 |
Why?
|
Blood Proteins | 1 | 2019 | 1124 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2013 | 17446 | 0.030 |
Why?
|
Albuminuria | 1 | 2018 | 682 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2020 | 3144 | 0.030 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2015 | 165 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2022 | 4933 | 0.030 |
Why?
|
Myositis | 1 | 2016 | 251 | 0.030 |
Why?
|
Computer Systems | 1 | 2015 | 483 | 0.030 |
Why?
|
Administration, Intranasal | 1 | 2015 | 446 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2000 | 1338 | 0.030 |
Why?
|
RNA Interference | 1 | 2022 | 2889 | 0.030 |
Why?
|
Polymers | 1 | 2020 | 1621 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2019 | 1683 | 0.030 |
Why?
|
Temperature | 1 | 2019 | 2206 | 0.030 |
Why?
|
Doxorubicin | 1 | 2019 | 2234 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 21683 | 0.030 |
Why?
|
Morbidity | 1 | 2018 | 1769 | 0.030 |
Why?
|
Glaucoma, Neovascular | 1 | 2012 | 36 | 0.030 |
Why?
|
Drug Delivery Systems | 1 | 2004 | 2219 | 0.030 |
Why?
|
Erythrocytes | 1 | 2022 | 2455 | 0.030 |
Why?
|
Health Surveys | 2 | 2013 | 4037 | 0.030 |
Why?
|
Capillary Permeability | 1 | 2016 | 798 | 0.030 |
Why?
|
Drug Costs | 1 | 2019 | 1105 | 0.030 |
Why?
|
Depth Perception | 1 | 2012 | 94 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2020 | 6386 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1654 | 0.020 |
Why?
|
Retirement | 1 | 2013 | 215 | 0.020 |
Why?
|
Tissue Engineering | 1 | 2021 | 1880 | 0.020 |
Why?
|
Arthritis | 1 | 2016 | 659 | 0.020 |
Why?
|
Central Nervous System Neoplasms | 1 | 2019 | 895 | 0.020 |
Why?
|
Numismatics | 1 | 2010 | 17 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2022 | 5524 | 0.020 |
Why?
|
Lebanon | 1 | 2011 | 229 | 0.020 |
Why?
|
Myocardial Infarction | 1 | 2012 | 11727 | 0.020 |
Why?
|
Cell Survival | 1 | 2020 | 5882 | 0.020 |
Why?
|
Stroke | 1 | 2013 | 9981 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2019 | 1889 | 0.020 |
Why?
|
HLA-DQ Antigens | 1 | 2010 | 210 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2018 | 2170 | 0.020 |
Why?
|
Triglycerides | 1 | 2018 | 2454 | 0.020 |
Why?
|
Th1 Cells | 1 | 2015 | 1057 | 0.020 |
Why?
|
Recovery of Function | 1 | 2020 | 2925 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2019 | 6622 | 0.020 |
Why?
|
Executive Function | 1 | 2018 | 1364 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2000 | 2585 | 0.020 |
Why?
|
ROC Curve | 1 | 2017 | 3527 | 0.020 |
Why?
|
Action Potentials | 1 | 2016 | 1806 | 0.020 |
Why?
|
Pyridines | 1 | 2020 | 2825 | 0.020 |
Why?
|
C-Peptide | 1 | 2010 | 419 | 0.020 |
Why?
|
Cholesterol | 1 | 2018 | 2917 | 0.020 |
Why?
|
Exercise Test | 1 | 2016 | 2074 | 0.020 |
Why?
|
Biopsy | 1 | 2020 | 6756 | 0.020 |
Why?
|
HLA-DR Antigens | 1 | 2010 | 645 | 0.020 |
Why?
|
Bronchiolitis | 1 | 2015 | 458 | 0.020 |
Why?
|
Periodicity | 1 | 2010 | 363 | 0.020 |
Why?
|
Protein Binding | 1 | 2020 | 9386 | 0.020 |
Why?
|
Thrombosis | 1 | 2022 | 2968 | 0.020 |
Why?
|
Contrast Media | 1 | 2021 | 5300 | 0.020 |
Why?
|
Oxidative Stress | 1 | 1999 | 3086 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 4186 | 0.020 |
Why?
|
Cytokines | 1 | 2022 | 7322 | 0.020 |
Why?
|
Physical Examination | 1 | 2013 | 1237 | 0.020 |
Why?
|
Specialization | 1 | 2012 | 777 | 0.020 |
Why?
|
Signal Transduction | 2 | 2020 | 23403 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2019 | 9734 | 0.020 |
Why?
|
Epithelial Cells | 1 | 1999 | 3690 | 0.020 |
Why?
|
Point-of-Care Systems | 1 | 2015 | 1177 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2019 | 3479 | 0.020 |
Why?
|
Health Care Costs | 1 | 2019 | 3209 | 0.020 |
Why?
|
Luciferases | 1 | 2008 | 733 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2000 | 11366 | 0.020 |
Why?
|
Phenotype | 2 | 2016 | 16365 | 0.020 |
Why?
|
Proteomics | 1 | 2019 | 3638 | 0.020 |
Why?
|
Observer Variation | 1 | 2012 | 2593 | 0.020 |
Why?
|
Viral Load | 1 | 2015 | 3299 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2010 | 2274 | 0.020 |
Why?
|
Medicare | 1 | 2023 | 6566 | 0.020 |
Why?
|
Patient Care Team | 1 | 2016 | 2531 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10252 | 0.020 |
Why?
|
Glioma | 1 | 2019 | 3401 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2016 | 3396 | 0.010 |
Why?
|
Genes, Reporter | 1 | 2008 | 1547 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2000 | 19229 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 2019 | 4256 | 0.010 |
Why?
|
Age of Onset | 1 | 2010 | 3271 | 0.010 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 1518 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2014 | 5974 | 0.010 |
Why?
|
Rats | 1 | 2000 | 24260 | 0.010 |
Why?
|
Electrocardiography | 1 | 2016 | 6442 | 0.010 |
Why?
|
Curriculum | 1 | 2016 | 3605 | 0.010 |
Why?
|
Vaccination | 1 | 2015 | 3278 | 0.010 |
Why?
|
Tissue and Organ Procurement | 1 | 2010 | 896 | 0.010 |
Why?
|
Genotype | 1 | 2016 | 12951 | 0.010 |
Why?
|
Haplotypes | 1 | 2008 | 2779 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 21827 | 0.010 |
Why?
|
Sex Factors | 1 | 2015 | 10397 | 0.010 |
Why?
|
Prevalence | 1 | 2018 | 15226 | 0.010 |
Why?
|
Prognosis | 2 | 2019 | 29063 | 0.010 |
Why?
|
Antihypertensive Agents | 1 | 2010 | 2046 | 0.010 |
Why?
|
Comorbidity | 1 | 2015 | 10388 | 0.010 |
Why?
|
Reference Values | 1 | 2008 | 4982 | 0.010 |
Why?
|
Body Mass Index | 1 | 2018 | 12720 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2009 | 1855 | 0.010 |
Why?
|
Cell Line | 2 | 2008 | 15997 | 0.010 |
Why?
|
RNA, Messenger | 2 | 2008 | 13033 | 0.010 |
Why?
|
Electrophoresis, Agar Gel | 1 | 1998 | 212 | 0.010 |
Why?
|
Health Status | 1 | 2012 | 4034 | 0.010 |
Why?
|
Electron Transport | 1 | 1999 | 211 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2016 | 7181 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2010 | 2872 | 0.010 |
Why?
|
Protein Phosphatase 2 | 1 | 1998 | 229 | 0.010 |
Why?
|
Alleles | 1 | 2008 | 6933 | 0.010 |
Why?
|
Pneumonia, Viral | 1 | 2015 | 3240 | 0.010 |
Why?
|
Lung | 1 | 2015 | 9856 | 0.010 |
Why?
|
Incidence | 1 | 2013 | 20947 | 0.010 |
Why?
|
DNA Primers | 1 | 1998 | 2892 | 0.010 |
Why?
|
Sequence Alignment | 1 | 1998 | 2256 | 0.010 |
Why?
|
Epithelium | 1 | 1998 | 1679 | 0.010 |
Why?
|
Models, Biological | 1 | 2010 | 9583 | 0.010 |
Why?
|
Child | 2 | 2018 | 77709 | 0.010 |
Why?
|
Kidney | 1 | 2008 | 7186 | 0.010 |
Why?
|
Down-Regulation | 1 | 1999 | 3002 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2008 | 12072 | 0.010 |
Why?
|
RNA | 1 | 1998 | 2749 | 0.010 |
Why?
|
Base Sequence | 1 | 1998 | 12797 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1998 | 18111 | 0.000 |
Why?
|
Child, Preschool | 1 | 1995 | 41006 | 0.000 |
Why?
|